Moreover, the 36-month beta value for SONN is 0.96. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SONN is 3.13M and currently, short sellers hold a 3.97% of that float. On May 23, 2025, SONN’s average trading volume was 41.52K shares.
SONN) stock’s latest price update
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN)’s stock price has dropped by -6.67 in relation to previous closing price of 1.20. Nevertheless, the company has seen a loss of -8.94% in its stock price over the last five trading days. globenewswire.com reported 2025-05-01 that PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.
SONN’s Market Performance
Sonnet BioTherapeutics Holdings Inc (SONN) has seen a -8.94% fall in stock performance for the week, with a -21.13% decline in the past month and a -22.22% plunge in the past quarter. The volatility ratio for the week is 4.64%, and the volatility levels for the past 30 days are at 4.17% for SONN. The simple moving average for the past 20 days is -14.79% for SONN’s stock, with a -63.44% simple moving average for the past 200 days.
SONN Trading at -14.92% from the 50-Day Moving Average
After a stumble in the market that brought SONN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.00% of loss for the given period.
Volatility was left at 4.17%, however, over the last 30 days, the volatility rate increased by 4.64%, as shares sank -17.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.42% lower at present.
During the last 5 trading sessions, SONN fell by -8.94%, which changed the moving average for the period of 200-days by -81.49% in comparison to the 20-day moving average, which settled at $1.3145. In addition, Sonnet BioTherapeutics Holdings Inc saw -23.29% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SONN
Current profitability levels for the company are sitting at:
- -12.48 for the present operating margin
- -3.15 for the gross margin
The net margin for Sonnet BioTherapeutics Holdings Inc stands at -12.03. The total capital return value is set at -20.81. Equity return is now at value -714.96, with -272.65 for asset returns.
Based on Sonnet BioTherapeutics Holdings Inc (SONN), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -128.49.
Currently, EBITDA for the company is -11.77 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 1.43. The receivables turnover for the company is 2.21for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To wrap up, the performance of Sonnet BioTherapeutics Holdings Inc (SONN) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
